Chen Xiaomei, Liu Bowen, Li Chao, Wang Yulian, Geng Suxia, Du Xin, Weng Jianyu, Lai Peilong
Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, PR China.
Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, PR China.
Int Immunopharmacol. 2023 Nov;124(Pt A):110890. doi: 10.1016/j.intimp.2023.110890. Epub 2023 Sep 7.
While The World Health Organization (WHO) has announced that COVID-19 is no longer a public health emergency of international concern(PHEIC), the risk of reinfection and new emerging variants still makes it crucial to study and work towards the prevention of COVID-19. Stem cell and stem cell-like derivatives have shown some promising results in clinical trials and preclinical studies as an alternative treatment option for the pulmonary illnesses caused by the COVID-19 and can be used as a potential vaccine. In this review, we will systematically summarize the pathophysiological process and potential mechanisms underlying stem cell-based therapy in COVID-19, and the registered COVID-19 clinical trials, and engineered extracellular vesicle as a potential vaccine for preventing COVID-19.
虽然世界卫生组织（WHO）已宣布新冠病毒不再构成国际关注的突发公共卫生事件（PHEIC），但再次感染和新出现变种的风险使得研究和致力于预防新冠病毒仍然至关重要。干细胞及类似干细胞的衍生物在临床试验和临床前研究中已显示出一些有前景的结果，可作为新冠病毒所致肺部疾病的替代治疗选择，并可用作潜在疫苗。在本综述中，我们将系统总结基于干细胞治疗新冠病毒的病理生理过程和潜在机制、已注册的新冠病毒临床试验，以及作为预防新冠病毒潜在疫苗的工程化细胞外囊泡。
